d) cleaving the protected Semaglutide using a reagent to obtain crude Semaglutide
Neuroprotection remains a formidable challenge, as every central nervous system (CNS) insult, be it stroke, trauma, or neurodegenerative disease, activates multiple, overlapping injury pathways
Semaglutide, a GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management, works by activating brain receptors that regulate hunger and slowing gastric emptying
Notably, the insulinotropic and glucagonostatic effects are glucose dependent, and therefore the risk of hypoglycemia is very low during treatment with a GLP-1 RA
Therefore, slower titration often leads to better adherence and sustained benefits